Do analysts rate CNTB or GNTA?

Connect Biopharma presently has a consensus target price of $7.29, indicating a potential upside of 222.38%. Given Connect Biopharma's stronger consensus rating and higher probable upside, analysts clearly believe Connect Biopharma is more favorable than Genenta Science. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Connect Biopharma 1 Sell rating(s) 0 Hold rating(s) 7 Buy rating(s) 1 Strong Buy rating(s) 2.89 Genenta Science 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Which has stronger valuation and earnings, CNTB or GNTA?

Genenta Science has lower revenue, but higher earnings than Connect Biopharma. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Connect Biopharma $60K 2,371.49 -$55.48M -$1.15 N/A Genenta Science N/A N/A -$7.39M N/A N/A

Is CNTB or GNTA more profitable?

Genenta Science's return on equity of 0.00% beat Connect Biopharma's return on equity. Company Net Margins Return on Equity Return on Assets Connect Biopharma N/A -122.29% -97.07% Genenta Science N/A N/A N/A

Does the media refer more to CNTB or GNTA?

In the previous week, Connect Biopharma had 4 more articles in the media than Genenta Science. MarketBeat recorded 6 mentions for Connect Biopharma and 2 mentions for Genenta Science. Genenta Science's average media sentiment score of 0.94 beat Connect Biopharma's score of 0.57 indicating that Genenta Science is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Connect Biopharma 1 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Genenta Science 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Do analysts prefer CUE or GNTA?

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Cue Biopharma 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 Genenta Science 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Which has preferable valuation and earnings, CUE or GNTA?

Genenta Science has lower revenue, but higher earnings than Cue Biopharma. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Cue Biopharma $27.47M 4.73 -$26.60M -$5.58 N/A Genenta Science N/A N/A -$7.39M N/A N/A

Does the media prefer CUE or GNTA?

In the previous week, Cue Biopharma had 6 more articles in the media than Genenta Science. MarketBeat recorded 8 mentions for Cue Biopharma and 2 mentions for Genenta Science. Genenta Science's average media sentiment score of 0.94 beat Cue Biopharma's score of 0.64 indicating that Genenta Science is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Cue Biopharma 1 Very Positive mention(s) 1 Positive mention(s) 5 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Genenta Science 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Do analysts rate GNTA or HURA?

TuHURA Biosciences has a consensus price target of $9.00, indicating a potential upside of 278.15%. Given TuHURA Biosciences' stronger consensus rating and higher probable upside, analysts clearly believe TuHURA Biosciences is more favorable than Genenta Science. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Genenta Science 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 TuHURA Biosciences 1 Sell rating(s) 0 Hold rating(s) 5 Buy rating(s) 0 Strong Buy rating(s) 2.67

Which has better valuation & earnings, GNTA or HURA?

Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Genenta Science N/A N/A -$7.39M N/A N/A TuHURA Biosciences N/A N/A -$30.05M -$0.61 N/A

Is GNTA or HURA more profitable?

Genenta Science's return on equity of 0.00% beat TuHURA Biosciences' return on equity. Company Net Margins Return on Equity Return on Assets Genenta Science N/A N/A N/A TuHURA Biosciences N/A -156.12% -105.38%

Does the media refer more to GNTA or HURA?

In the previous week, Genenta Science and Genenta Science both had 2 articles in the media. TuHURA Biosciences' average media sentiment score of 1.68 beat Genenta Science's score of 0.94 indicating that TuHURA Biosciences is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Genenta Science 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive TuHURA Biosciences 1 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Very Positive

Do analysts rate GNTA or PEPG?

PepGen has a consensus price target of $11.50, suggesting a potential upside of 371.31%. Given PepGen's stronger consensus rating and higher probable upside, analysts plainly believe PepGen is more favorable than Genenta Science. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Genenta Science 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 PepGen 1 Sell rating(s) 0 Hold rating(s) 6 Buy rating(s) 0 Strong Buy rating(s) 2.71

Which has better earnings & valuation, GNTA or PEPG?

Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Genenta Science N/A N/A -$7.39M N/A N/A PepGen N/A N/A -$89.65M -$1.75 N/A

Is GNTA or PEPG more profitable?

Genenta Science's return on equity of 0.00% beat PepGen's return on equity. Company Net Margins Return on Equity Return on Assets Genenta Science N/A N/A N/A PepGen N/A -59.89% -49.62%

Does the media prefer GNTA or PEPG?

In the previous week, PepGen had 1 more articles in the media than Genenta Science. MarketBeat recorded 3 mentions for PepGen and 2 mentions for Genenta Science. Genenta Science's average media sentiment score of 0.94 beat PepGen's score of 0.93 indicating that Genenta Science is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Genenta Science 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive PepGen 0 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Which has better valuation and earnings, SPRB or GNTA?

Genenta Science has lower revenue, but higher earnings than Spruce Biosciences. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Spruce Biosciences $4.91M 27.10 -$38.97M -$36.60 N/A Genenta Science N/A N/A -$7.39M N/A N/A

Is SPRB or GNTA more profitable?

Genenta Science's return on equity of 0.00% beat Spruce Biosciences' return on equity. Company Net Margins Return on Equity Return on Assets Spruce Biosciences N/A -155.40% -101.67% Genenta Science N/A N/A N/A

Does the media prefer SPRB or GNTA?

In the previous week, Spruce Biosciences had 4 more articles in the media than Genenta Science. MarketBeat recorded 6 mentions for Spruce Biosciences and 2 mentions for Genenta Science. Spruce Biosciences' average media sentiment score of 1.05 beat Genenta Science's score of 0.94 indicating that Spruce Biosciences is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Spruce Biosciences 1 Very Positive mention(s) 2 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Genenta Science 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Genenta Science (GNTA) Competitors

$1.32 -0.18 (-12.00%)

Closing price 07/13/2026 04:00 PM Eastern

Extended Trading

$1.32 +0.00 (+0.38%)

As of 07:35 AM Eastern

Compare

GNTA vs. CNTB, CUE, HURA, PEPG, and SPRB

Should you buy Genenta Science stock or one of its competitors? MarketBeat compares Genenta Science with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Genenta Science include Connect Biopharma (CNTB), Cue Biopharma (CUE), TuHURA Biosciences (HURA), PepGen (PEPG), and Spruce Biosciences (SPRB). These companies are all part of the "pharmaceutical products" industry.

How does Genenta Science compare to Connect Biopharma?

Connect Biopharma (NASDAQ:CNTB) and Genenta Science (NASDAQ:GNTA) are both small-cap medical companies, but which is the better business? We will contrast the two businesses based on the strength of their earnings, media sentiment, risk, valuation, profitability, analyst recommendations, institutional ownership and dividends.

In the previous week, Connect Biopharma had 4 more articles in the media than Genenta Science. MarketBeat recorded 6 mentions for Connect Biopharma and 2 mentions for Genenta Science. Genenta Science's average media sentiment score of 0.94 beat Connect Biopharma's score of 0.57 indicating that Genenta Science is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Connect Biopharma	1 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Genenta Science	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Connect Biopharma has a beta of -0.23, indicating that its stock price is 123% less volatile than the broader market. Comparatively, Genenta Science has a beta of 0.75, indicating that its stock price is 25% less volatile than the broader market.

Genenta Science's return on equity of 0.00% beat Connect Biopharma's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Connect Biopharma	N/A	-122.29%	-97.07%
Genenta Science	N/A	N/A	N/A

Connect Biopharma presently has a consensus target price of $7.29, indicating a potential upside of 222.38%. Given Connect Biopharma's stronger consensus rating and higher probable upside, analysts clearly believe Connect Biopharma is more favorable than Genenta Science.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Connect Biopharma	1 Sell rating(s)	0 Hold rating(s)	7 Buy rating(s)	1 Strong Buy rating(s)	2.89
Genenta Science	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

58.7% of Connect Biopharma shares are owned by institutional investors. Comparatively, 15.1% of Genenta Science shares are owned by institutional investors. 22.6% of Connect Biopharma shares are owned by insiders. Comparatively, 29.0% of Genenta Science shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

Genenta Science has lower revenue, but higher earnings than Connect Biopharma.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Connect Biopharma	$60K	2,371.49	-$55.48M	-$1.15	N/A
Genenta Science	N/A	N/A	-$7.39M	N/A	N/A

Summary

Connect Biopharma beats Genenta Science on 7 of the 13 factors compared between the two stocks.

How does Genenta Science compare to Cue Biopharma?

Cue Biopharma (NASDAQ:CUE) and Genenta Science (NASDAQ:GNTA) are both small-cap medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their profitability, valuation, risk, dividends, institutional ownership, media sentiment, analyst recommendations and earnings.

In the previous week, Cue Biopharma had 6 more articles in the media than Genenta Science. MarketBeat recorded 8 mentions for Cue Biopharma and 2 mentions for Genenta Science. Genenta Science's average media sentiment score of 0.94 beat Cue Biopharma's score of 0.64 indicating that Genenta Science is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Cue Biopharma	1 Very Positive mention(s)	1 Positive mention(s)	5 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Genenta Science	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Cue Biopharma has a beta of 2.45, indicating that its stock price is 145% more volatile than the broader market. Comparatively, Genenta Science has a beta of 0.75, indicating that its stock price is 25% less volatile than the broader market.

Genenta Science has lower revenue, but higher earnings than Cue Biopharma.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Cue Biopharma	$27.47M	4.73	-$26.60M	-$5.58	N/A
Genenta Science	N/A	N/A	-$7.39M	N/A	N/A

Genenta Science has a net margin of 0.00% compared to Cue Biopharma's net margin of -59.65%. Genenta Science's return on equity of 0.00% beat Cue Biopharma's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Cue Biopharma	-59.65%	-98.30%	-53.69%
Genenta Science	N/A	N/A	N/A

35.0% of Cue Biopharma shares are held by institutional investors. Comparatively, 15.1% of Genenta Science shares are held by institutional investors. 14.6% of Cue Biopharma shares are held by company insiders. Comparatively, 29.0% of Genenta Science shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Cue Biopharma	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Genenta Science	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

Summary

Genenta Science beats Cue Biopharma on 6 of the 10 factors compared between the two stocks.

How does Genenta Science compare to TuHURA Biosciences?

Genenta Science (NASDAQ:GNTA) and TuHURA Biosciences (NASDAQ:HURA) are both small-cap medical companies, but which is the superior business? We will compare the two companies based on the strength of their media sentiment, valuation, dividends, institutional ownership, analyst recommendations, risk, profitability and earnings.

In the previous week, Genenta Science and Genenta Science both had 2 articles in the media. TuHURA Biosciences' average media sentiment score of 1.68 beat Genenta Science's score of 0.94 indicating that TuHURA Biosciences is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Genenta Science	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
TuHURA Biosciences	1 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Very Positive

15.1% of Genenta Science shares are held by institutional investors. Comparatively, 0.6% of TuHURA Biosciences shares are held by institutional investors. 29.0% of Genenta Science shares are held by company insiders. Comparatively, 6.1% of TuHURA Biosciences shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Genenta Science	N/A	N/A	-$7.39M	N/A	N/A
TuHURA Biosciences	N/A	N/A	-$30.05M	-$0.61	N/A

Genenta Science's return on equity of 0.00% beat TuHURA Biosciences' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Genenta Science	N/A	N/A	N/A
TuHURA Biosciences	N/A	-156.12%	-105.38%

Genenta Science has a beta of 0.75, indicating that its share price is 25% less volatile than the broader market. Comparatively, TuHURA Biosciences has a beta of -0.05, indicating that its share price is 105% less volatile than the broader market.

TuHURA Biosciences has a consensus price target of $9.00, indicating a potential upside of 278.15%. Given TuHURA Biosciences' stronger consensus rating and higher probable upside, analysts clearly believe TuHURA Biosciences is more favorable than Genenta Science.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Genenta Science	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
TuHURA Biosciences	1 Sell rating(s)	0 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.67

Summary

Genenta Science beats TuHURA Biosciences on 6 of the 10 factors compared between the two stocks.

How does Genenta Science compare to PepGen?

Genenta Science (NASDAQ:GNTA) and PepGen (NASDAQ:PEPG) are both small-cap medical companies, but which is the superior business? We will contrast the two businesses based on the strength of their analyst recommendations, profitability, risk, institutional ownership, valuation, dividends, media sentiment and earnings.

PepGen has a consensus price target of $11.50, suggesting a potential upside of 371.31%. Given PepGen's stronger consensus rating and higher probable upside, analysts plainly believe PepGen is more favorable than Genenta Science.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Genenta Science	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
PepGen	1 Sell rating(s)	0 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.71

15.1% of Genenta Science shares are held by institutional investors. Comparatively, 58.0% of PepGen shares are held by institutional investors. 29.0% of Genenta Science shares are held by insiders. Comparatively, 1.3% of PepGen shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Genenta Science	N/A	N/A	-$7.39M	N/A	N/A
PepGen	N/A	N/A	-$89.65M	-$1.75	N/A

In the previous week, PepGen had 1 more articles in the media than Genenta Science. MarketBeat recorded 3 mentions for PepGen and 2 mentions for Genenta Science. Genenta Science's average media sentiment score of 0.94 beat PepGen's score of 0.93 indicating that Genenta Science is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Genenta Science	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
PepGen	0 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Genenta Science has a beta of 0.75, meaning that its share price is 25% less volatile than the broader market. Comparatively, PepGen has a beta of 1.88, meaning that its share price is 88% more volatile than the broader market.

Genenta Science's return on equity of 0.00% beat PepGen's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Genenta Science	N/A	N/A	N/A
PepGen	N/A	-59.89%	-49.62%

Summary

PepGen beats Genenta Science on 6 of the 11 factors compared between the two stocks.

How does Genenta Science compare to Spruce Biosciences?

Spruce Biosciences (NASDAQ:SPRB) and Genenta Science (NASDAQ:GNTA) are both small-cap medical companies, but which is the better stock? We will compare the two companies based on the strength of their media sentiment, valuation, profitability, institutional ownership, earnings, dividends, risk and analyst recommendations.

Genenta Science has lower revenue, but higher earnings than Spruce Biosciences.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Spruce Biosciences	$4.91M	27.10	-$38.97M	-$36.60	N/A
Genenta Science	N/A	N/A	-$7.39M	N/A	N/A

In the previous week, Spruce Biosciences had 4 more articles in the media than Genenta Science. MarketBeat recorded 6 mentions for Spruce Biosciences and 2 mentions for Genenta Science. Spruce Biosciences' average media sentiment score of 1.05 beat Genenta Science's score of 0.94 indicating that Spruce Biosciences is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Spruce Biosciences	1 Very Positive mention(s)	2 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Genenta Science	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Genenta Science's return on equity of 0.00% beat Spruce Biosciences' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Spruce Biosciences	N/A	-155.40%	-101.67%
Genenta Science	N/A	N/A	N/A

Spruce Biosciences has a beta of 3.16, indicating that its stock price is 216% more volatile than the broader market. Comparatively, Genenta Science has a beta of 0.75, indicating that its stock price is 25% less volatile than the broader market.

Spruce Biosciences presently has a consensus target price of $162.63, suggesting a potential upside of 236.14%. Given Spruce Biosciences' stronger consensus rating and higher possible upside, equities research analysts plainly believe Spruce Biosciences is more favorable than Genenta Science.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Spruce Biosciences	1 Sell rating(s)	2 Hold rating(s)	8 Buy rating(s)	0 Strong Buy rating(s)	2.64
Genenta Science	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

91.7% of Spruce Biosciences shares are owned by institutional investors. Comparatively, 15.1% of Genenta Science shares are owned by institutional investors. 4.3% of Spruce Biosciences shares are owned by company insiders. Comparatively, 29.0% of Genenta Science shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

Summary

Spruce Biosciences beats Genenta Science on 8 of the 12 factors compared between the two stocks.

Get Genenta Science News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding GNTA and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

GNTA vs. The Competition

Export

Metric	Genenta Science	MED Industry	Medical Sector	NASDAQ Exchange
Market Cap	$35.39M	$3.71B	$7.05B	$12.61B
Dividend Yield	N/A	2.20%	2.68%	8.00%
P/E Ratio	N/A	20.85	27.12	24.26
Price / Sales	N/A	314.01	587.25	117.88
Price / Cash	N/A	61.98	29.22	49.36
Price / Book	1.02	8.49	10.89	6.29
Net Income	-$7.39M	$23.83M	$3.58B	$330.66M
7 Day Performance	-18.01%	-3.56%	-2.11%	-1.35%
1 Month Performance	-29.41%	6.31%	3.28%	-0.64%
1 Year Performance	-65.08%	48.30%	26.33%	19.08%

Genenta Science Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
GNTA Genenta Science	0.7442 of 5 stars	$1.32 -12.0%	N/A	-66.7%	$35.39M	N/A	N/A	7	Gap Down
CNTB Connect Biopharma	4.4226 of 5 stars	$2.29 +3.6%	$7.17 +213.0%	+48.7%	$144.18M	$60K	N/A	110	News Coverage
CUE Cue Biopharma	0.3004 of 5 stars	$33.88 +1.5%	N/A	-95.5%	$142.30M	$27.47M	N/A	60	News Coverage Gap Down
HURA TuHURA Biosciences	3.1494 of 5 stars	$2.22 -1.1%	$9.00 +306.3%	+3.5%	$141.06M	N/A	N/A	N/A	Positive News
PEPG PepGen	2.5729 of 5 stars	$2.02 -1.7%	$11.50 +470.7%	+93.7%	$139.17M	N/A	N/A	30	News Coverage

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:GNTA) was last updated on 7/14/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Genenta Science (GNTA) Competitors

GNTA vs. CNTB, CUE, HURA, PEPG, and SPRB

How does Genenta Science compare to Connect Biopharma?

Summary

How does Genenta Science compare to Cue Biopharma?

Summary

How does Genenta Science compare to TuHURA Biosciences?

Summary

How does Genenta Science compare to PepGen?

Summary

How does Genenta Science compare to Spruce Biosciences?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

GNTA vs. The Competition

Genenta Science Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Genenta Science (GNTA) Competitors

GNTA vs. CNTB, CUE, HURA, PEPG, and SPRB

How does Genenta Science compare to Connect Biopharma?

Does the media refer more to CNTB or GNTA?

Which has more risk & volatility, CNTB or GNTA?

Is CNTB or GNTA more profitable?

Do analysts rate CNTB or GNTA?

Do institutionals & insiders believe in CNTB or GNTA?

Which has stronger valuation and earnings, CNTB or GNTA?

Summary

How does Genenta Science compare to Cue Biopharma?

Does the media prefer CUE or GNTA?

Which has more risk & volatility, CUE or GNTA?

Which has preferable valuation and earnings, CUE or GNTA?

Is CUE or GNTA more profitable?

Do insiders and institutionals believe in CUE or GNTA?

Do analysts prefer CUE or GNTA?

Summary

How does Genenta Science compare to TuHURA Biosciences?

Does the media refer more to GNTA or HURA?

Do institutionals and insiders believe in GNTA or HURA?

Which has better valuation & earnings, GNTA or HURA?

Is GNTA or HURA more profitable?

Which has more volatility and risk, GNTA or HURA?

Do analysts rate GNTA or HURA?

Summary

How does Genenta Science compare to PepGen?

Do analysts rate GNTA or PEPG?

Do insiders & institutionals have more ownership in GNTA or PEPG?

Which has better earnings & valuation, GNTA or PEPG?

Does the media prefer GNTA or PEPG?

Which has more volatility & risk, GNTA or PEPG?

Is GNTA or PEPG more profitable?

Summary

How does Genenta Science compare to Spruce Biosciences?

Which has better valuation and earnings, SPRB or GNTA?

Does the media prefer SPRB or GNTA?

Is SPRB or GNTA more profitable?

Which has more volatility & risk, SPRB or GNTA?

Do analysts prefer SPRB or GNTA?

Do insiders and institutionals have more ownership in SPRB or GNTA?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

GNTA vs. The Competition

Genenta Science Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools